S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.93 (-1.12%)
MSFT   330.15 (+0.02%)
FB   309.00 (-0.52%)
GOOGL   2,859.77 (+1.37%)
AMZN   3,444.00 (+0.01%)
TSLA   1,077.00 (-1.64%)
NVDA   322.16 (+2.48%)
BABA   120.26 (-1.82%)
NIO   34.59 (-9.71%)
CGC   9.95 (+0.10%)
AMD   150.17 (+0.71%)
GE   95.16 (+2.32%)
MU   82.77 (-2.80%)
T   23.11 (+3.96%)
F   19.83 (+1.28%)
DIS   146.27 (+2.90%)
PFE   53.33 (-2.47%)
AMC   29.73 (+4.06%)
ACB   5.96 (-0.83%)
BA   198.49 (+5.47%)
NASDAQ:RTTR

Ritter Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.46
-0.01 (-0.68%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.39
$1.56
50-Day Range
$0.45
$4.09
52-Week Range
$0.15
$1.27
Volume
5.48 million shs
Average Volume
14.23 million shs
Market Capitalization
$67.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.43

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Ritter Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ritter Pharmaceuticals logo

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Headlines

Ritter to complete Qualigen tie-up today
May 22, 2020 |  seekingalpha.com
RTTR Ritter Pharmaceuticals, Inc. Common Stock
May 7, 2020 |  www.nasdaq.com
66 Biggest Movers From Yesterday
May 7, 2020 |  www.msn.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RTTR
Fax
N/A
Employees
7
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.10 per share

Profitability

Net Income
$-10.13 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$67.38 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/01/2020
Today
12/02/2021

MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

1224th out of 1,391 stocks

Pharmaceutical Preparations Industry

586th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01.
View Ritter Pharmaceuticals' earnings history
.

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Ritter Pharmaceuticals's stock reverse split on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the following people:
  • Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
  • Mr. Michael D. Step, Consultant & Director (Age 59)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
  • Ms. Ellen F. Mochizuki, Consultant (Age 52)

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and (PRMW).

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $1.46.

How much money does Ritter Pharmaceuticals make?

Ritter Pharmaceuticals has a market capitalization of $67.38 million.

How many employees does Ritter Pharmaceuticals have?

Ritter Pharmaceuticals employs 7 workers across the globe.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is www.ritterpharmaceuticals.com.

Where are Ritter Pharmaceuticals' headquarters?

Ritter Pharmaceuticals is headquartered at 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.